Literature DB >> 10483914

The glial scar and central nervous system repair.

J W Fawcett1, R A Asher.   

Abstract

Damage to the central nervous system (CNS) results in a glial reaction, leading eventually to the formation of a glial scar. In this environment, axon regeneration fails, and remyelination may also be unsuccessful. The glial reaction to injury recruits microglia, oligodendrocyte precursors, meningeal cells, astrocytes and stem cells. Damaged CNS also contains oligodendrocytes and myelin debris. Most of these cell types produce molecules that have been shown to be inhibitory to axon regeneration. Oligodendrocytes produce NI250, myelin-associated glycoprotein (MAG), and tenascin-R, oligodendrocyte precursors produce NG2 DSD-1/phosphacan and versican, astrocytes produce tenascin, brevican, and neurocan, and can be stimulated to produce NG2, meningeal cells produce NG2 and other proteoglycans, and activated microglia produce free radicals, nitric oxide, and arachidonic acid derivatives. Many of these molecules must participate in rendering the damaged CNS inhibitory for axon regeneration. Demyelinated plaques in multiple sclerosis consists mostly of scar-type astrocytes and naked axons. The extent to which the astrocytosis is responsible for blocking remyelination is not established, but astrocytes inhibit the migration of both oligodendrocyte precursors and Schwann cells which must restrict their access to demyelinated axons.

Entities:  

Mesh:

Year:  1999        PMID: 10483914     DOI: 10.1016/s0361-9230(99)00072-6

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  441 in total

1.  Two-tiered inhibition of axon regeneration at the dorsal root entry zone.

Authors:  M S Ramer; I Duraisingam; J V Priestley; S B McMahon
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

2.  Neurocan is upregulated in injured brain and in cytokine-treated astrocytes.

Authors:  R A Asher; D A Morgenstern; P S Fidler; K H Adcock; A Oohira; J E Braistead; J M Levine; R U Margolis; J H Rogers; J W Fawcett
Journal:  J Neurosci       Date:  2000-04-01       Impact factor: 6.167

3.  NG2 is a major chondroitin sulfate proteoglycan produced after spinal cord injury and is expressed by macrophages and oligodendrocyte progenitors.

Authors:  Leonard L Jones; Yu Yamaguchi; William B Stallcup; Mark H Tuszynski
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

4.  Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery.

Authors:  C P Hofstetter; E J Schwarz; D Hess; J Widenfalk; A El Manira; Darwin J Prockop; L Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

Review 5.  Astrocytes and stroke: networking for survival?

Authors:  Michelle F Anderson; Fredrik Blomstrand; Christian Blomstrand; P S Eriksson; Michael Nilsson
Journal:  Neurochem Res       Date:  2003-02       Impact factor: 3.996

Review 6.  Neurotrophic factors, cellular bridges and gene therapy for spinal cord injury.

Authors:  L L Jones; M Oudega; M B Bunge; M H Tuszynski
Journal:  J Physiol       Date:  2001-05-15       Impact factor: 5.182

7.  IT delivery of ChABC modulates NG2 and promotes GAP-43 axonal regrowth after spinal cord injury.

Authors:  I Novotna; L Slovinska; I Vanicky; M Cizek; J Radonak; D Cizkova
Journal:  Cell Mol Neurobiol       Date:  2011-06-01       Impact factor: 5.046

8.  Astrogliosis: a target for intervention in intracerebral hemorrhage?

Authors:  Sangeetha Sukumari-Ramesh; Cargill H Alleyne; Krishnan M Dhandapani
Journal:  Transl Stroke Res       Date:  2012-04-14       Impact factor: 6.829

9.  Controlling fibrous capsule formation through long-term down-regulation of collagen type I (COL1A1) expression by nanofiber-mediated siRNA gene silencing.

Authors:  Pim-on Rujitanaroj; Brian Jao; Junghoon Yang; Feng Wang; James M Anderson; Jun Wang; Sing Yian Chew
Journal:  Acta Biomater       Date:  2012-10-02       Impact factor: 8.947

10.  Correlation of Versican Expression, Accumulation, and Degradation during Embryonic Development by Quantitative Immunohistochemistry.

Authors:  Jessica M Snyder; Ida M Washington; Timothy Birkland; Mary Y Chang; Charles W Frevert
Journal:  J Histochem Cytochem       Date:  2015-09-18       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.